Innosuisse Awards CorFlow a CHF 1.7M Public Grant

The Innosuisse Grant is Awarded to CorFlow for the MOCA I Clinical Trial and Translational Research

CorFlow logo
(PresseBox) ( Baar, )
CorFlow Therapeutics AG ("CorFlow") today announced that Innosuisse, the Swiss Innovation Agency, has awarded the Company a non-dilutive public grant. The grant is a continuation of the successfully completed non-clinical project which was granted by CTI/Innosuisse in January 2017. Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland. The total grant is CHF 1.7M (USD 1.7M) and runs over 2 years.

The project "Translational development of a medical device to treat microvascular obstruction in heart attack patients" is in cooperation with Prof. Dominik Obrist (University of Bern, ARTORG Center of Biomedical Engineering Research), Prof. André Bernard (University of Applied Sciences Buchs NTB), Prof. Sebastian Kozerke (University and ETH Zurich, Inst. for Biomedical Engineering), Dr.med.vet. Nikola Cesarovic (University Hospital Zürich, Division of Surgical Research) and Prof. Marco Valgimigli (Bern University Hospital, Inselspital).

The project lead Prof. Obrist said: "We are grateful that Innosuisse recognised our vision for the technology's potential to be moved to the next stage, by providing funding for the project at this pivotal stage. With the financial contributions from Innosuisse and CorFlow, the project will allow us to further deepen our understanding of the coronary microcirculation. The unique, interdisciplinary research consortium brings together unique capabilities in magnetic resonance imaging, circulatory modelling, non-clinical research and clinical trials which will be instrumental to bring the CorFlow technology into the hands of clinicians and to impact patient care".

Prof. Valgimigli, who is the principal investigator of the First-in-Man (FIM) clinical trial to be conducted in Switzerland, commented: "Microvascular obstruction is an unmet need for acute heart attack patients and we have to date not had tools to promptly diagnose it and treat it in patients after stent placement. We are excited to join the consortium and take the lead on the clinical implementation of the CorFlow technology".

In addition to the Innosuisse grant, CorFlow is contributing substantial funds for the continued technical and clinical development of the first generation CorFlow Controlled Flow Infusion (CoFITM) console and rapid exchange (RX) catheter. The dossier for the FIM clinical trial called MOCA I (Microvascular Obstruction with the CoFI System Assessment) has been submitted for approval to Swiss authorities. The Company targets enrolment of the first patient in the MOCA I trial in 2019 and will provide regular updates on the progress of the study.  

Jon H. Hoem, CorFlow's CEO and co-Founder, commented: "The continued and substantial support from Innosuisse is very welcome and the project will form the basis for a Swiss expert centre studying the human microcirculation. Further non-clinical and clinical research are needed to deepen our understanding of the human microcirculation and CorFlow is pleased to be a part of these efforts. We look forward to continue and expand our cooperation with scientists world-wide who share our passion for a deeper understanding of effective treatments of microvascular dysfunction which affects hundreds of thousands of patients every year".
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.